Evaluation of low-dose intraperitoneal interferon-α for palliation of ascites in patients with non-ovarian gynecologic malignancies

Dineo Khabele, Carolyn D. Runowicz, Abbie L. Fields, Patrick S. Anderson, Gary L. Goldberg

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Objective. Intraperitoneal interferon-α (IP-IFNα) has shown some benefit in the treatment of patients with ovarian cancer. Our goal was to evaluate the use of low-dose IP-IFNα for the palliative control of ascites in non-ovarian gynecologic malignancies, including primary peritoneal and uterine papillary serous carcinomas. Methods. Fifteen patients with non-ovarian gynecologic malignancies received one or two doses of 10 MU (10 × 106 U/m2) of IP-IFNα via single-use drum catheter for the symptomatic control of ascites. The median age for this patient group was 61 years (range 40-84). Histopathologic diagnoses were confirmed on all patients. Eleven of 15 (73%) patients had uterine cancers. Four of 15 (27%) patients had papillary serous primary peritoneal carcinomas. Thirteen of 15 (87%) patients had Stage III disease or more. All patients had been heavily pretreated with chemotherapy and all had progressive disease. Results. Specific parameters used to evaluate IP-IFNα were (1) median survival; (2) number of days to recurrent ascites; (3) number of subsequent paracenteses required for symptomatic relief; and (4) symptomatology and side effects. Median overall survival was 3 months (range 0.5-13). Seven of 15 (47%) patients survived >3 months. Twelve of 15 (80%) patients had recurrent ascites within 30 days of treatment. However, 3/15 (20%) patients had a prolonged, >30-day period, without symptomatic ascites. One patient (6%) had a 270-day response with no ascites. Toxicity was minimal from IP-IFNα infusion. The most common side effect was fever in 6/15 (40%) patients. Conclusion. IP-IFNα was well tolerated and may have some benefit in a subset of patients. Although 80% of patients had recurrent ascites within 30 days, 20% had a prolonged, >30-day response. Further study is warranted to determine the role of immune modulators, such as IP-IFNα, in the palliative management of patients with non-ovarian gynecologic malignancies that cause ascites.

Original languageEnglish (US)
Pages (from-to)420-423
Number of pages4
JournalGynecologic Oncology
Volume89
Issue number3
DOIs
StatePublished - Jun 1 2003

Fingerprint

Ascites
Interferons
Neoplasms
Parenteral Infusions
Paracentesis
Uterine Neoplasms
Survival
Papillary Carcinoma
Ovarian Neoplasms
Fever
Catheters

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Oncology

Cite this

Evaluation of low-dose intraperitoneal interferon-α for palliation of ascites in patients with non-ovarian gynecologic malignancies. / Khabele, Dineo; Runowicz, Carolyn D.; Fields, Abbie L.; Anderson, Patrick S.; Goldberg, Gary L.

In: Gynecologic Oncology, Vol. 89, No. 3, 01.06.2003, p. 420-423.

Research output: Contribution to journalArticle

Khabele, Dineo ; Runowicz, Carolyn D. ; Fields, Abbie L. ; Anderson, Patrick S. ; Goldberg, Gary L. / Evaluation of low-dose intraperitoneal interferon-α for palliation of ascites in patients with non-ovarian gynecologic malignancies. In: Gynecologic Oncology. 2003 ; Vol. 89, No. 3. pp. 420-423.
@article{6d4b0ffb4c6d4eadbf9612326f6c0711,
title = "Evaluation of low-dose intraperitoneal interferon-α for palliation of ascites in patients with non-ovarian gynecologic malignancies",
abstract = "Objective. Intraperitoneal interferon-α (IP-IFNα) has shown some benefit in the treatment of patients with ovarian cancer. Our goal was to evaluate the use of low-dose IP-IFNα for the palliative control of ascites in non-ovarian gynecologic malignancies, including primary peritoneal and uterine papillary serous carcinomas. Methods. Fifteen patients with non-ovarian gynecologic malignancies received one or two doses of 10 MU (10 × 106 U/m2) of IP-IFNα via single-use drum catheter for the symptomatic control of ascites. The median age for this patient group was 61 years (range 40-84). Histopathologic diagnoses were confirmed on all patients. Eleven of 15 (73{\%}) patients had uterine cancers. Four of 15 (27{\%}) patients had papillary serous primary peritoneal carcinomas. Thirteen of 15 (87{\%}) patients had Stage III disease or more. All patients had been heavily pretreated with chemotherapy and all had progressive disease. Results. Specific parameters used to evaluate IP-IFNα were (1) median survival; (2) number of days to recurrent ascites; (3) number of subsequent paracenteses required for symptomatic relief; and (4) symptomatology and side effects. Median overall survival was 3 months (range 0.5-13). Seven of 15 (47{\%}) patients survived >3 months. Twelve of 15 (80{\%}) patients had recurrent ascites within 30 days of treatment. However, 3/15 (20{\%}) patients had a prolonged, >30-day period, without symptomatic ascites. One patient (6{\%}) had a 270-day response with no ascites. Toxicity was minimal from IP-IFNα infusion. The most common side effect was fever in 6/15 (40{\%}) patients. Conclusion. IP-IFNα was well tolerated and may have some benefit in a subset of patients. Although 80{\%} of patients had recurrent ascites within 30 days, 20{\%} had a prolonged, >30-day response. Further study is warranted to determine the role of immune modulators, such as IP-IFNα, in the palliative management of patients with non-ovarian gynecologic malignancies that cause ascites.",
author = "Dineo Khabele and Runowicz, {Carolyn D.} and Fields, {Abbie L.} and Anderson, {Patrick S.} and Goldberg, {Gary L.}",
year = "2003",
month = "6",
day = "1",
doi = "10.1016/S0090-8258(03)00080-5",
language = "English (US)",
volume = "89",
pages = "420--423",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "3",

}

TY - JOUR

T1 - Evaluation of low-dose intraperitoneal interferon-α for palliation of ascites in patients with non-ovarian gynecologic malignancies

AU - Khabele, Dineo

AU - Runowicz, Carolyn D.

AU - Fields, Abbie L.

AU - Anderson, Patrick S.

AU - Goldberg, Gary L.

PY - 2003/6/1

Y1 - 2003/6/1

N2 - Objective. Intraperitoneal interferon-α (IP-IFNα) has shown some benefit in the treatment of patients with ovarian cancer. Our goal was to evaluate the use of low-dose IP-IFNα for the palliative control of ascites in non-ovarian gynecologic malignancies, including primary peritoneal and uterine papillary serous carcinomas. Methods. Fifteen patients with non-ovarian gynecologic malignancies received one or two doses of 10 MU (10 × 106 U/m2) of IP-IFNα via single-use drum catheter for the symptomatic control of ascites. The median age for this patient group was 61 years (range 40-84). Histopathologic diagnoses were confirmed on all patients. Eleven of 15 (73%) patients had uterine cancers. Four of 15 (27%) patients had papillary serous primary peritoneal carcinomas. Thirteen of 15 (87%) patients had Stage III disease or more. All patients had been heavily pretreated with chemotherapy and all had progressive disease. Results. Specific parameters used to evaluate IP-IFNα were (1) median survival; (2) number of days to recurrent ascites; (3) number of subsequent paracenteses required for symptomatic relief; and (4) symptomatology and side effects. Median overall survival was 3 months (range 0.5-13). Seven of 15 (47%) patients survived >3 months. Twelve of 15 (80%) patients had recurrent ascites within 30 days of treatment. However, 3/15 (20%) patients had a prolonged, >30-day period, without symptomatic ascites. One patient (6%) had a 270-day response with no ascites. Toxicity was minimal from IP-IFNα infusion. The most common side effect was fever in 6/15 (40%) patients. Conclusion. IP-IFNα was well tolerated and may have some benefit in a subset of patients. Although 80% of patients had recurrent ascites within 30 days, 20% had a prolonged, >30-day response. Further study is warranted to determine the role of immune modulators, such as IP-IFNα, in the palliative management of patients with non-ovarian gynecologic malignancies that cause ascites.

AB - Objective. Intraperitoneal interferon-α (IP-IFNα) has shown some benefit in the treatment of patients with ovarian cancer. Our goal was to evaluate the use of low-dose IP-IFNα for the palliative control of ascites in non-ovarian gynecologic malignancies, including primary peritoneal and uterine papillary serous carcinomas. Methods. Fifteen patients with non-ovarian gynecologic malignancies received one or two doses of 10 MU (10 × 106 U/m2) of IP-IFNα via single-use drum catheter for the symptomatic control of ascites. The median age for this patient group was 61 years (range 40-84). Histopathologic diagnoses were confirmed on all patients. Eleven of 15 (73%) patients had uterine cancers. Four of 15 (27%) patients had papillary serous primary peritoneal carcinomas. Thirteen of 15 (87%) patients had Stage III disease or more. All patients had been heavily pretreated with chemotherapy and all had progressive disease. Results. Specific parameters used to evaluate IP-IFNα were (1) median survival; (2) number of days to recurrent ascites; (3) number of subsequent paracenteses required for symptomatic relief; and (4) symptomatology and side effects. Median overall survival was 3 months (range 0.5-13). Seven of 15 (47%) patients survived >3 months. Twelve of 15 (80%) patients had recurrent ascites within 30 days of treatment. However, 3/15 (20%) patients had a prolonged, >30-day period, without symptomatic ascites. One patient (6%) had a 270-day response with no ascites. Toxicity was minimal from IP-IFNα infusion. The most common side effect was fever in 6/15 (40%) patients. Conclusion. IP-IFNα was well tolerated and may have some benefit in a subset of patients. Although 80% of patients had recurrent ascites within 30 days, 20% had a prolonged, >30-day response. Further study is warranted to determine the role of immune modulators, such as IP-IFNα, in the palliative management of patients with non-ovarian gynecologic malignancies that cause ascites.

UR - http://www.scopus.com/inward/record.url?scp=0038173765&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0038173765&partnerID=8YFLogxK

U2 - 10.1016/S0090-8258(03)00080-5

DO - 10.1016/S0090-8258(03)00080-5

M3 - Article

C2 - 12798705

AN - SCOPUS:0038173765

VL - 89

SP - 420

EP - 423

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 3

ER -